Mkt Cap$2.26T-0.77%
24h Vol$46.05B
BTC Dom56.5%
ETH Dom8.9%
F&G18Extreme Fear
BTC$63,742.00-0.63% ETH$1,662.41-0.87% USDT$0.9994-0.01% BNB$603.87-0.64% USDC$0.9998+0.00% XRP$1.13-1.13% SOL$67.43-0.95% TRX$0.3188+0.47% FIGR_HELOC$1.02-1.41% HYPE$60.33+0.91% DOGE$0.0863-1.49% USDS$0.9997-0.01% LEO$9.72+0.83% RAIN$0.013+0.39% ZEC$424.29+2.30% XMR$341.04-1.04% BTC$63,742.00-0.63% ETH$1,662.41-0.87% USDT$0.9994-0.01% BNB$603.87-0.64% USDC$0.9998+0.00% XRP$1.13-1.13% SOL$67.43-0.95% TRX$0.3188+0.47% FIGR_HELOC$1.02-1.41% HYPE$60.33+0.91% DOGE$0.0863-1.49% USDS$0.9997-0.01% LEO$9.72+0.83% RAIN$0.013+0.39% ZEC$424.29+2.30% XMR$341.04-1.04%
Earnings

AngioDynamics Stock Drops 24% After Q2 Earnings Report

AngioDynamics reported Q2 FY24 with $81.97M in sales and revised annual guidance to $320-$325M amidst market challenges.

Tim Fries
Tim Fries Tim Fries is the cofounder of
Jan 5, 2024 2 min read
AngioDynamics Stock Drops 18% After Q2 Earnings Report
Image courtesy of 123rf.com
Editorial disclosureRead more

All reviews, research, news and assessments of any kind on The Tokenist are compiled using a strict editorial review process by our editorial team. Neither our writers nor our editors receive direct compensation of any kind to publish information on tokenist.com. Our company, Tokenist Media LLC, is community supported and may receive a small commission when you purchase products or services through links on our website. Click here for a full list of our partners and an in-depth explanation on how we get paid.

Neither the author, Tim Fries, nor this website, The Tokenist, provide financial advice. Please consult our website policy prior to making financial decisions.

AngioDynamics Inc. (NASDAQ: ANGO) reported its performance for the second quarter of fiscal 2024. The company achieved net sales of $81.97 million, a significant increase from the previous quarter. The company’s updated fiscal year guidance projects net sales of $320 to $325 million, reflecting strategic adjustments in operations and market conditions.

ANGO Reports -$0.05 EPS for Q2 FY24

AngioDynamics’ Q2 performance stood out, especially when compared against the market expectations of an EPS of -$0.08 and revenue of $81.97 million. The company met these expectations and demonstrated the potential for future growth and profitability. AngoDynamics reported a loss of $0.05 per share and revenue of $79.1 million for the period.

Join our Telegram group and never miss a breaking digital asset story.

ANGO Revises Guidance for Net Sales to Be $320M to $325M

The firm provided revised guidance for fiscal year 2024, forecasting net sales to be $320 to $325 million. This adjustment reflects the softer thrombectomy sales during the fiscal second quarter and anticipated impacts from manufacturing restructuring.

The company anticipates a gross margin of approximately 49% to 51% and an adjusted loss per share in the $0.35 to $0.42 range. This guidance indicates a strategic focus on optimizing operations while navigating current market challenges.

Following the Q2 fiscal 2024 earnings release, AngioDynamics’ stock price showed significant movement. The stock previously closed at $12.38 and experienced a notable decrease in premarket trading after the earnings report, dropping to $5.85, a 24.51% decline at the time of writing.

ANGO Earnings stocks
Tim Fries

Tim Fries

Author · Tokenist

Tim Fries is the cofounder of The Tokenist. He has a B. Sc. in Mechanical Engineering from the University of Michigan, and an MBA from the University of Chicago Booth School of Business. Tim served as a Senior Associate on the investment team at RW Baird's US Private Equity division, and is also the co-founder of Protective Technologies Capital, an investment firm specializing in sensing, protection and control solutions.

Related Stories